Multiple Myeloma Management
10+
Downloads
Everyone
info
About this app
Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
No data collected
Learn more about how developers declare collection
What’s new
Updates to UI and target platforms
App support
About the developer
Med Learning Group, LLC
rmukalian@ccfv.com
1325 Avenue Of The Americas Fl 28
New York, NY 10019
United States
+1 610-291-8889
